News | May 24, 2024
Taro shareholders approve merger with Sun Pharma
The combined entity will enable us to better serve the needs of patients, healthcare professionals and our customers around the world
The combined entity will enable us to better serve the needs of patients, healthcare professionals and our customers around the world
Before joining Gland, Loomba was associated with Shalina Labs, Harman Finochem, Aurobindo Pharma, Sun Pharmaceuticals and Ranabaxy Laboratories.
Sun Pharma's Dadra facility receives OAI status from US FDA
Mungara has over 25+ years of experience in the supply chain domain
Bromfenac Ophthalmic Solution 0.075% (RLD BromSite) had estimated annual sales of USD 15 million in the U.S.
This recognition attests to Sun Pharma’s commitment to incorporate Environmental, Social, and Governance (ESG) principles through focused initiatives across its businesses
Agreed Price of US$43 per share to deliver 48% premium to unaffected price on May 25, 2023
Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa
According to Sun Pharma, the purpose of the strategic investment is to obtain access to the technology for certain compounds and territories while also fostering the development of novel pharmaceutical delivery systems.
Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners
Subscribe To Our Newsletter & Stay Updated
